Consensus Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/04/2026 am IST			5-day change	1st Jan Change
153.40 ^USD	+1.50%		-6.35%	-11.86%

14/04	Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says	MT
14/04	RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating	MT

Evolution of the Average Target: Insmed Incorporated

Evolution of the Target Price: Insmed Incorporated

Changes in Analyst Recommendations: Insmed Incorporated

1c6d454250e1.y8SQ-O10gI3494b0qpQKaHQcV3T5rIhkx9x-jDTJAjE.r5Wmjpkh6NzNxLGW8u5rDzJZBR-fz98Fnbs9wgyjU2Szpqih2hfs4Yqzvg~0c3292b670cf59b09d4455ad493c5107

Analysts' recommendations: Insmed Incorporated

14/04	Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says	MT
14/04	RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating	MT
08/04	Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating	MT
07/04	RBC Capital Adjusts Price Target on Insmed to $212 From $203, Maintains Outperform Rating	MT
31/03	UBS Adjusts Price Target on Insmed to $185 From $215, Maintains Buy Rating	MT
30/03	Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says	MT
30/03	Morgan Stanley Upgrades Insmed to Overweight From Equalweight, Raises Price Target to $212 From $166	MT
30/03	Analyst recommendations: AMD, Expedia, Instacart, Coinbase, Elf beauty…
24/03	Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating	MT
23/02	Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating	MT
20/02	Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says	MT
20/02	Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says	MT
20/02	Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating	MT
28/01	Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target	MT
23/01	Roth Capital Initiates Coverage on Insmed With Buy Rating, $212 Price Target	MT
21/01	RBC Raises Price Target on Insmed to $200 From $197, Keeps Outperform Rating	MT
08/01	RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating	MT
06/01	UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating	MT
18/12	Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says	MT
18/12	Mizuho Adjusts Price Target on Insmed to $212 From $256, Maintains Outperform Rating	MT
18/12	RBC Lowers Price Target on Insmed to $195 From $215, Keeps Outperform Rating	MT
18/12	Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron…
04/12	Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target	MT
01/12	Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating	MT
31/25/31	Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INSMED INCORPORATED					+40.37%
	ARGENX SE					+24.26%
	WUXI APPTEC CO., LTD.					+27.35%
	BIONTECH SE					+36.65%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.62%
	GENMAB A/S					+24.34%
	AKESO, INC.					+26.39%
	SUMMIT THERAPEUTICS INC.					+51.48%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.45%
	MADRIGAL PHARMACEUTICALS, INC.					+27.18%
	Average					+29.81%
	Weighted average by Cap.					+29.80%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

151.14USD

Average target price

212.35USD

Spread / Average Target

+40.50%

High Price Target

243.00USD

Spread / Highest target

+60.78%

Low Price Target

177.00USD

Spread / Lowest Target

+17.11%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
RBC Capital Markets
UBS
Morgan Stanley
Barclays
Roth Capital Partners
Rothschild & Co Redburn
Truist Securities
William Blair & Co.
BofA Securities
Jefferies & Co.
Evercore ISI
JPMorgan Chase
Stifel Nicolaus
Wolfe Research
TD Cowen
Goldman Sachs
Wells Fargo Securities
HC Wainwright
Cantor Fitzgerald
Guggenheim
Cowen
Berenberg Bank
SVB Leerink
Credit Suisse